The aspartic acid protease encoded by human immunodeficiency virus (HIV) is critical for replication of the virus (4, 11) . This enzyme is responsible for specific cleavages of the viralgag andgag-pol gene products, which are precursors of essential viral structural proteins and essential enzymes, including reverse transcriptase, integrase, and the protease itself (3, 17, 19) . Inhibition of this enzyme by synthetic inhibitors during infection in vitro leads to a reduction in the number of infectious virus particles produced (13) . This is presumably due primarily to incomplete processing of the p55gag polyprotein to the essential structural proteins p24, p17, p7, and p6.
To date, most inhibitors of the HIV aspartic acid protease have been transition state mimetics. These have included reduced amides (5, 14) , hydroxyethylene isosteres (5, 18, 23, 24) , statine analogs (5), phosphinic acid derivatives (6) , and difluoroketone derivatives (5, 21) .
XM323 represents a new class of protease inhibitors that are referred to as cyclic ureas. The description of the design, synthesis, and characteristics of this class of protease inhibitors will be published elsewhere (12) . These compounds lack the amide bonds found in previous inhibitors but retain the symmetry of the potent C-2 symmetrical diols (10) . XM323 is a potent inhibitor of purified HIV type 1 (HIV-1) protease, with a Ki of 0.27 nM (12) . In this report, we present the anti-HIV activity of this compound as determined by three different measurements. Efficacy was determined by effects on the production of viral RNA, p24 antigen, and infectious virus. The susceptibilities of laboratory strains of HIV-1, HIV-2, and clinical isolates of HIV-1 were assessed. (Fig. 1 ). Q8111 is a compound synthesized by DuPont Merck chemists to be equivalent to from Roche. YY752 is a compound synthesized by DuPont Merck chemists to be equivalent to A80987 (9) from Abbott Laboratories. Zidovudine (AZT) was obtained from Burroughs Wellcome, and ddC was purchased from Sigma.
HIV yield reduction assay. MT-2, a human T-cell leukemia virus type 1-transformed human T-cell line, was cultured in RPMI 1640 medium supplemented with 5% (vol/vol) heatinactivated fetal bovine serum (FBS), 2 mM L-glutamine, and 5 ,ug of gentamicin per ml. HIV strains HIV-1(IIIB), HIV-1(RF), and HIV-2(ROD) were propagated in H9 cells, a T-cell lymphoma cell line, in RPMI 1640 with 5% FBS. Routine testing for mycoplasma (2) ensured that all experiments were performed with mycoplasma-free MT-2 and H9 cells. Poly-L-lysine (Sigma)-coated cell culture plates were prepared according to the method of Harada et al. (7) . MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was obtained from Sigma.
Test compounds were dissolved in dimethyl sulfoxide (DMSO) to 5 mg/ml and serially diluted into RPMI 1640 medium to lOx the desired final concentration for a final concentration of DMSO of c0.5%. This concentration of DMSO was found to have no effect on the yield of infectious virus in this assay. MT-2 cells (5 x 105/ml) in 2.3 ml were mixed with 0. Approximately 107 patient PBMCs were added to an equal number of the target cells in RPMI 1640 with 10% FBS and 1,000 U of IL-2 per ml. The cultures were incubated at 36°C in 5% CO2 in a T-25 tissue culture flask. Approximately i07 fresh target cells were added every 7 days, and half of the medium was changed twice weekly. Cultures were routinely expanded to a T-75 flask during the second week. Infections were monitored for formation of syncytia visually and through p24 antigen determinations at least twice weekly as described below. Cultures were maintained for at least 4 weeks before being discarded as negative. Aliquots of positive cultures were transferred to 1.8-ml cryovials (Nalge Co., Rochester, N.Y.) and stored in liquid nitrogen.
Titration of virus stock for PBMC assay. Virus stocks were titrated after serial fourfold dilutions in a 96-well microtiter plate. Normal donor phytohemagglutinin-and IL-2-stimulated PBMCs in RPMI 1640 medium (10% FBS, 1,000 U of IL-2 per ml) were added to each well at 2 x 105 cells per well. Plates were incubated at 36°C in 5% CO2. On day 4, cells were resuspended and approximately half of the culture was replaced with fresh medium. On day 7, Triton X-100 was added to a final concentration of 0.5% to lyse cells and inactivate virus. Plates with cell lysates were frozen at -70°C until p24 antigen could be determined. After plates were thawed, 100 ,ul of supernatant fluid was transferred to a fresh 96-well microtiter plate containing 100 ,ul of RPMI 1640 per well. The p24 antigen concentration was determined with the DuPont, NEN HIV-1 p24 antigen capture assay. Wells were scored positive if the p24 concentration was >50 pg/ml, and 50% tissue culture infective doses for the virus stocks were determined.
AIDS Clinical Trials Group-Department of Defense PBMC consensus assay. The consensus assay used in this study was developed cooperatively by members of the AIDS Clinical Trials Group and the U.S. Department of Defense (8) . Test compounds were prepared as described above. Phytohemagglutinin-and IL-2-stimulated donor PBMCs (1.6 x 107) in RPMI 1640 were infected with 1.6 x 104 50% tissue culture infective doses of virus (MOI, -0.001) and incubated at 36°C for 1 h. Unadsorbed virus in the supernatant fluid was removed after centrifugation. The infected cells were resuspended in fresh medium, and aliquots were distributed in microtiter plate wells (0.2 x 106 cells per 100 ,ul per well), which had been prepared by the addition of 100 ,ul of graded concentrations of test compounds per well in triplicate.
Plates were incubated at 36°C in 5% CO2 for 4 days, at which time 125 ,ul of cells plus medium was removed and 150 ,ul of RPMI 1640 containing the appropriate concentration of compound was added. After incubation for an additional 3 days, 20 pl of the supernatant fluid was serially diluted to a final dilution of 1:156 in medium with a final concentration of Triton X-100 of 0.5%. Plates were stored frozen at -70'C until p24 antigen assays were performed. The p24 antigen values of the untreated controls and sample wells were measured by the DuPont, NEN enzyme-linked immunosorbent assay. The optical density readings of the no-drug controls were averaged to determine the value for the untreated control. The concentrations of compound producing a 50 or 90% reduction in the amount of p24 antigen (IC50 or IC90, respectively) were determined.
HIV RNA hybridization assay. The HIV RNA hybridization assay was performed as follows (1) . MT More important, XM323 shows a dose-dependent inhibition of virus replication over a wide range of concentrations (Fig.  2) . XM323 reduced the yield of HIV-1(RF) by 3 to 4 log units at concentrations as low as 1.8 ,uM (1 ,ug/ml).
Efficacy against laboratory strains and clinical isolates of HIV-1 by PBMC assay. The ability of XM323 and AZT to inhibit the replication of laboratory strains and clinical isolates of HIV-1 in the AIDS Clinical Trial Group-Department of Defense PBMC consensus assay is shown in Table  2 . In this assay, p24 antigen production from virus-infected PBMCs is measured over a range of compound concentrations and the IC50 and IC90 are determined. This concentration was over 600 times the IC90 for HIV-1 in these cells. Efficacy against HIV-1(RF) by the RNA hybridization assay. The ability of XM323 to inhibit the replication of HIV-1(RF) in MT-2 cells was determined with the HIV RNA hybridization assay. In this assay, the accumulation of HIV gag RNA sequences in infected cells was measured over a range of compound concentrations, and the IC90 was determined. The antiviral efficacy of XM323 in this assay was compared with the antiviral efficacies of two inhibitors of the viral reverse transcriptase (AZT and ddC) and two additional inhibitors of the virally encoded protease, Q8111 (a compound synthesized by DuPont Merck to be equivalent to Ro31-8959) (18) and YY752 (a compound synthesized by DuPont Merck to be equivalent to A80987) (9) . Table 3 shows the IC90s from these assays. The IC90 for XM323 against HIV-1(RF) was 0.063 ,uM. XM323 was more potent than the nucleoside analogs AZT and ddC, slightly more potent than the protease inhibitor YY752, but less potent than the protease inhibitor Q8111.
Effect of MOI on the anti-HIV activity of XM323. With many antiviral agents, the ability to inhibit virus replication is inversely proportional to the inoculum size. If cells are challenged at a high MOI, more compound is often required to achieve a given percentage of inhibition than if the cells are challenged with less virus. In order to determine the effect of MOI on the potency of XM323, the standard yield reduction assay was performed but with different levels of viral inoculum. For comparison, the assays were conducted with AZT as well. Table 4 shows the results of these tests. 
DISCUSSION
XM323 represents a novel class of potent inhibitors of HIV protease. By using a rational drug design approach, a class of inhibitors unlike any previously described that are cyclic in structure and contain no peptide bonds was designed. Crystallographic structural studies of HIV-1 protease-cyclic urea complexes have shown that these inhibitors bind with high affinity in a unique manner. In addition to 
